IMR Press / FBL / Volume 29 / Issue 4 / DOI: 10.31083/j.fbl2904161
Open Access Review
A Review: The Significance of Toll-Like Receptors 2 and 4, and NF-κB Signaling in Endothelial Cells during Atherosclerosis
Show Less
1 Department of Cardiology, Second Affiliated Hospital of Shantou University Medical College, 515000 Shantou, Guangdong, China
2 Shantou University Medical College, 515000 Shantou, Guangdong, China
*Correspondence: lijilin@126.com (Jilin Li)
These authors contributed equally.
Front. Biosci. (Landmark Ed) 2024, 29(4), 161; https://doi.org/10.31083/j.fbl2904161
Submitted: 12 November 2023 | Revised: 6 February 2024 | Accepted: 18 March 2024 | Published: 23 April 2024
(This article belongs to the Special Issue Toll-Like Receptors in Various Pathologies)
Copyright: © 2024 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.
Abstract

Atherosclerosis (AS) is a chronic inflammatory vascular disease that begins with endothelial activation followed by a series of inflammatory responses, plaque formation, and finally rupture. An early event in endothelial dysfunction is activation of the nuclear factor-κB (NF-κB) signaling axis. Toll-like receptors (TLRs) in endothelial cells (ECs) play an essential role in recognizing pathogen-associated molecular patterns (PAMPs), damage-associated molecular patterns (DAMPs), and lifestyle-associated molecular patterns (LAMPs). Activation of the canonical NF-κB pathway stimulates the expression of cytokines, chemokines, and an array of additional genes which activate and amplify AS-associated inflammatory responses. In this review, we discuss the involvement of TLR2/4 and NF-κB signaling in ECs during AS initiation, as well as regulation of the inflammatory response during AS by noncoding RNAs, especially microRNA (miRNA) and circular RNA (circRNA).

Keywords
TLR2
TLR4
NF-κB
atherosclerosis
Funding
[2019]113-55(190826155555147)/Special Fund Project for Science and Technology Innovation Strategy of Guangdong Province
[2020]66 (ST2020027)/Shantou Medical Health Science and Technology Plan
Figures
Fig. 1.
Share
Back to top